TCMD — Tactile Systems Technology, Inc.

Summary of TCMD Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $329.5 million for the full year, a 12% increase year-over-year; Q4 revenue of $103.6 million, up 21% year-over-year.
• Gross Margin: Expanded by 190 basis points to 75.9% for the full year; Q4 gross margin at 78.2%, up from 75.2% in Q4 2024.
• Adjusted EBITDA: Increased by 21% year-over-year to $44.8 million for the full year; Q4 adjusted EBITDA of $22 million compared to $16.2 million.
• Net Income: Rose to $10.6 million ($0.46 per diluted share), up from $9.7 million ($0.40 per diluted share).
• Cash Position: Ended 2025 with $83.4 million in cash and cash equivalents, having repaid a $26.3 million term loan and repurchased $26.5 million of stock.

2. Strategic Updates and Business Highlights

• Lymphedema Business: Revenue grew 16% year-over-year, driven by strong execution of the go-to-market strategy and increased sales rep productivity.
• Airway Clearance Products: Revenue surged 66% year-over-year, attributed to heightened awareness and demand for AffloVest.
• Acquisition of LymphaTech: This acquisition enhances Tactile's capabilities in lymphedema solutions, integrating digital 3D scanning technology for improved patient assessment and monitoring.
• Strategic Priorities: Focus on improving access to care, expanding treatment options, and enhancing lifetime patient value through technology and workflow improvements.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $357 million and $365 million, reflecting 8% to 11% growth year-over-year.
• Impact of Medicare Changes: Anticipated short-term challenges due to new prior authorization requirements for pneumatic compression devices, which may temporarily affect market growth.
• Q1 2026 Outlook: Growth expected to be higher than the rest of the year, with a moderation in growth rates as the year progresses.

4. Bad News, Challenges, or Points of Concern

• Prior Authorization Requirement: New Medicare requirement for prior authorization may slow down patient access and create administrative burdens, impacting short-term growth.
• Market Dynamics: The prior authorization process could introduce delays in therapy access, particularly as Medicare adjusts to the new requirements.
• Potential for Slower Growth: While the company is well-positioned to navigate these changes, there is concern about how the prior authorization process may affect overall market dynamics and growth rates.

5. Notable Q&A Insights

• Lymphedema Business Performance: Management highlighted that the combination of increased sales rep hiring, improved CRM adoption, and favorable Medicare policies contributed to strong Q4 performance.
• Balancing Headwinds and Tailwinds: The management emphasized a balanced approach in their guidance, considering both the positive impacts of the NCD and the challenges posed by the new prior authorization.
• LymphaTech Integration: The acquisition is expected to enhance Tactile's market position and streamline workflows, with plans to integrate LymphaTech's technology into Tactile's sales strategy.
• Airway Clearance Growth: The company sees continued potential in the airway clearance market, driven by increased awareness and the complementary nature of drug therapies with their devices.

Overall, Tactile Medical demonstrated strong financial performance in 2025, with strategic initiatives positioning the company for future growth despite upcoming challenges in the reimbursement landscape.